{"disease":{"id":"lymphoma-nonhodgkin","name":"lymphoma nonhodgkin"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03971305","title":"A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04618081","title":"Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)","phase":"","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT05097443","title":"Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Shandong Provincial Hospital","has_results":false},{"nct_id":"NCT03483103","title":"Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":true},{"nct_id":"NCT06462248","title":"Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Chi Kong Li","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}